Positive early results accelerate timeline and reduce capital needs by up to $15 million
Envoy Medical (COCH), a Minnesota-based hearing health company developing fully implanted hearing solutions, announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of its pivotal clinical trial for the Acclaim® cochlear implant to the final stage. The decision follows promising three-month data from the first 10 trial participants, marking a major milestone for the company.
With the FDA’s approval, Envoy can now move forward with full enrollment ahead of schedule. The company expects to complete enrollment by early 2026, shortening its overall development timeline by three to six months. This acceleration is expected to reduce its capital requirements by $10–15 million.
“The FDA’s approval to expand our pivotal trial is a game-changing milestone,” said Brent Lucas, CEO of Envoy Medical. “Our data demonstrated strong progress, and we’re now on a faster path toward redefining the standard of care in cochlear implants.”
The first phase of the study involved 10 patients at five U.S. sites, all of whom successfully completed their three-month evaluations with no serious adverse events. The device was tested in a “cochlear implant only” mode—without external hearing aids—and met performance expectations.
The second and final stage will include 46 additional participants at seven U.S. trial sites. Given strong patient interest, Envoy anticipates rapid enrollment.
The company sees significant market potential: of the 2.8 million U.S. adults eligible for cochlear implants, fewer than 5% currently receive them. Envoy believes its fully implanted design—eliminating bulky external hardware—can drive broader adoption and help millions regain hearing confidence.
Shares of Envoy Medical surged following the announcement, reflecting optimism over its accelerated regulatory progress.
You might like this article:Tech Rally Lifts S&P 500 and Nasdaq as AMD Soars on OpenAI Deal
